RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+9.61%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.63B
AUM Growth
+$6.63B
(+3.5%)
Cap. Flow
-$77.8M
Cap. Flow
% of AUM
-1.17%
Top 10 Holdings %
Top 10 Hldgs %
45.03%
Holding
125
New
14
Increased
22
Reduced
8
Closed
12
Top Buys
| 1 |
ESSA Pharma
EPIX
|
$79.1M |
| 2 |
Masimo
MASI
|
$56.1M |
| 3 |
Regenxbio
RGNX
|
$52.1M |
| 4 |
GH Research
GHRS
|
$42.7M |
| 5 |
Guardant Health
GH
|
$38.3M |
Top Sells
| 1 |
CERN
Cerner Corp
CERN
|
$128M |
| 2 |
Arvinas
ARVN
|
$107M |
| 3 |
Immunovant
IMVT
|
$102M |
| 4 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$72.3M |
| 5 |
Curis
CRIS
|
$41M |
Sector Composition
| 1 | Healthcare | 88.48% |
| 2 | Financials | 0.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $664M | 10.02% | 14,990,286 -725,000 | -5% | -$32.1M |
|
2
SPDR S&P 500 ETF Trust
SPY
$658B
| $426M | 6.44% | 996,255 +50,000 | +5% | +$21.4M |
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $285M | 4.31% | 1,683,362 | – | – |
|
|
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $281M | 4.24% | 7,521,859 +58,568 | +0.8% | +$2.19M |
|
5
Vericel Corp
VCEL
$1.83B
| $237M | 3.58% | 4,517,570 | – | – |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $235M | 3.55% | 1,457,532 +124,300 | +9% | +$20.1M |
|
7
Illumina
ILMN
$15.8B
| $228M | 3.45% | 482,791 +835 | +0.2% | +$395K |
|
8
PTC Therapeutics
PTCT
$3.92B
| $224M | 3.38% | 5,293,966 | – | – |
|
9
Establishment Labs
ESTA
$1.2B
| $203M | 3.06% | 2,319,138 | – | – |
|
|
10
Masimo
MASI
$7.59B
| $200M | 3.02% | 826,210 +231,254 | +39% | +$56.1M |
|
11
Natera
NTRA
$23.1B
| $194M | 2.93% | 1,712,234 | – | – |
|
12
Protagonist Therapeutics
PTGX
$3.67B
| $157M | 2.38% | 3,507,390 | – | – |
|
13
10x Genomics
TXG
$1.74B
| $144M | 2.17% | 734,481 +22,966 | +3% | +$4.5M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $131M | 1.97% | 3,908,947 | – | – |
|
|
DMTK
15
DELISTED
DermTech, Inc. Common Stock
DMTK
| $130M | 1.96% | 3,118,665 | – | – |
|
16
Globus Medical
GMED
$8.27B
| $130M | 1.95% | 1,670,811 | – | – |
|
|
AXNX
17
DELISTED
Axonics, Inc. Common Stock
AXNX
| $123M | 1.86% | 1,943,864 +60,000 | +3% | +$3.8M |
|
18
Stoke Therapeutics
STOK
$1.08B
| $123M | 1.85% | 3,644,248 | – | – |
|
|
19
Guardant Health
GH
$8.41B
| $114M | 1.72% | 918,253 +308,479 | +51% | +$38.3M |
|
20
QuidelOrtho
QDEL
$1.95B
| $113M | 1.7% | 878,533 | – | – |
|
21
Tandem Diabetes Care
TNDM
$845M
| $112M | 1.69% | 1,147,408 +8,178 | +0.7% | +$797K |
|
22
Axsome Therapeutics
AXSM
$6.05B
| $109M | 1.65% | 1,616,497 | – | – |
|
23
Avidity Biosciences
RNA
$5.99B
| $98.7M | 1.49% | 3,995,000 | – | – |
|
|
24
ESSA Pharma
EPIX
$11.4M
| $87.3M | 1.32% | 3,053,919 +2,770,227 | +976% | +$79.1M |
|
25
C4 Therapeutics
CCCC
$185M
| $81.3M | 1.23% | 2,149,228 | – | – |
|